Navigation Links
InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
Date:4/1/2008

- Rapid and significant reductions in HCV RNA observed; well tolerated in

all dose cohorts - - Significant progress made in clinical, preclinical and formulation --

- Conference call and webcast today at 8:30 a.m. EDT --

BRISBANE, Calif., April 1, 2008 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today provided an overall program update and reported the top-line results from the four dose cohorts of treatment-naive patients in its ongoing Phase 1b clinical trial of ITMN-191, designated R7227 at Roche (SWX: ROG). ITMN-191 was administered as monotherapy in patients with chronic hepatitis C virus (HCV) genotype 1 infection. InterMune reported that treatment with ITMN-191 resulted in rapid and significant reductions in HCV RNA (see table below).

Total Daily Mean Maximum Reduction

Cohort Dose Dose (mg) HCV RNA Log10 IU/mL (range)

1 100 mg q12h 200 1.6 (0.9-2.2)

2 100 mg q8h 300 2.6 (1.7-3.6)

3 200 mg q12h 400 3.4 (2.4-4.4)

4 200 mg q8h 600 3.9 (3.0-5.0)

One final cohort consisting of treatment-experienced patients dosed at 300mg every 12 hours will begin dosing next week.

InterMune additionally reported that, based on a preliminary review of the available and still blinded clinical data from the four completed cohorts of the Phase 1b study, ITMN-191 was safe and well-tolerated. No serious adverse events were reported and no subject discontinued the study due to an adverse event. Adverse events were generally mild and transient in nature.

"With rapid and s
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. InterMune Announces Start of Phase 1b Trial of ITMN-191
2. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
3. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
4. Kingfisher Announces FDA 510(k) Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers
5. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline Update
8. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
9. Poniard Pharmaceuticals Announces Commercial Manufacturing Agreement With W. C. Heraeus GmbH for Picoplatin
10. Nventa Announces Positive Interim Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
11. Anacor Pharmaceuticals Announces Positive Results from Phase 2a Clinical Trial of AN2728 in Psoriasis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)...wswire-FirstCall/ -- Ardea Biosciences, Inc.,(Nasd... "RDEA119, a Potent,and Highly Selective MEK1/2 In...SS) -- induced Chronic Colitis in Mice," was prese...ACG) 2008 Annual Meeting in Orlando,Florida. The ...dy of,RDEA119, the Company,s lead mitogen-activate...
(Date:10/6/2008)... /- Pharmasset, Inc.,(Nasda...., is joining the,Company as Vice President of Inv...Smith will be responsible for all investor relatio...ancial Officer Kurt,Leutzinger., Most recently, D...logy,Analyst at JPMorgan Securities, and has been ...
(Date:10/6/2008)... feature children, parents discussing clinical ...., Oct. 6 /PRNewswire-USNewswire/ -- From asthma a...dren saves lives and improves their,health and wel...es of,Health (NIH), "Children and Clinical Studies...h.gov ), offers parents and health,care providers ...
(Date:10/6/2008)...Oct. 6 /- Genaera,Corporati...econd Phase 1,clinical trial of trodusquemine (MSI...tment of type 2 diabetes and obesity. MSI-1436 is ...target that controls the function,of both the lept...ecrease,appetite. In the study, MSI-1436 was found...
Breaking Medicine Technology:Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 2Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 4Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 2Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 3Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 4 New discovery leaves blood doping athletes scratching their heads 1667 1 New discovery leaves blood doping athletes scratching their heads 1667 2ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 472 1ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 472 2ASPB announces Summer Undergraduate Research Fellowship 2007 recipients 472 3Genetic variation affects smoking cessation treatment 1663 1Genetic variation affects smoking cessation treatment 1663 2Moffitt Selects Microsofts Azyxxi to Help Drive Personalized Cancer Treatment 1661 1Moffitt Selects Microsofts Azyxxi to Help Drive Personalized Cancer Treatment 1661 2
...lyses To Be Presented --, SAN FRANCISCO, April 24,...oday announced that data from the Company,s Phase,...ease will be,presented for the first time in the U...s 59th Annual Meeting in Boston on Thursday,May 3... include new,data from both the mild and moderate ...
...., April 24, 2007 /PRNewswire/ -- Accera Inc.,anno...tudy of its,lead compound AC-1202 in Alzheimer,s d...g of the American Academy of Neurology (AAN) in,Bo...ent of the,program, the data will also be featured...ccera,s vice president of clinical development Dr....
Other Medicine Technology:Medivation Announces First U.S. Presentation of Data From Dimebon,Phase 2 Alzheimer's Disease Trial at American Academy of Neurology,Annual Meeting 2Medivation Announces First U.S. Presentation of Data From Dimebon,Phase 2 Alzheimer's Disease Trial at American Academy of Neurology,Annual Meeting 3Accera, Inc. to Present Results of Phase II Study in Alzheimer's,Disease at American Academy of Neurology Meeting 2
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...ering potentially fatal liver complications from c...y are given before a stem cell transplant// such a...tment. But chemotherapy causes five to 50 per cent...al complication called veno-occlusive disease (VOD...
... was observed that carbohydrates that originate in...ause arthritis.// Researchers from Harvard Medical...ed GAGs to the defense system in the body that cau...s been a mystery, this new finding may shed light ...
...American Journal of Clinical Nutrition it was obse...preventing the build up of plaque in the arteries ...h has shown antioxidant vitamins can protect again...ries. However, most studies have concentrated on p...
...evels of air pollution can trigger a heart attack ... for more than 24 hours. Researchers say that expo...lutants increased the risk of a heart attack by 40...who are most vulnerable are those already at risk ...
Other Medicine News:
Bandeau Bra
Bras and Breast Support
Compression Bra
Constructed from soft Shur-grip foam and velcro closure for easy application and - reapplication
Medicine Products: